CASE DISCUSSION
A Practical Approach to Antenatal Hydronephrosis
Presented by Dr. Vivek VishwanathanViews
390
Credit Points
Learning Hours
CPD Points
CME Points
Courses Completed
Case Description
Antenatal hydronephrosis is one of the most frequently detected fetal anomalies on prenatal ultrasound, requiring a structured approach to evaluation and follow-up. This session will provide a practical overview of its prenatal diagnosis, risk stratification, postnatal assessment, and...
Case Summary
- Antenatal hydronephrosis affects 1 to 5 percent of pregnancies, necessitating a precise approach to differentiate transient physiological dilatation from significant pathology like posterior urethral valves, high-grade vesicoureteral reflux, or obstruction. The majority of mild cases resolve spontaneously, while severe cases carry risks of renal parenchymal loss, pulmonary hypoplasia, and end-stage kidney disease. Mastery of the Urinary Tract Dilation classification system is essential, as it provides a standardized framework for risk stratification that outperforms older grading systems.
Speaker Profile
Dr. Vivek Vishwanathan
Consultant Pediatric Urologist, Dhiraj Hospital, Vadodara Assistant Professor, Sumandeep Vidyapeeth, VadodaraDr. Vivek Vishwanathan is a Consultant Pediatric Urologist at Dhiraj Hospital, Vadodara, and serves as an Assistant Professor at Sumandeep Vidyapeeth, Vadodara. He specializes in the diagnosis and management of congenital and acquired urological disorders in children, with expertise in minimally invasive and reconstructive pediatric urology. Actively involved in clinical practice, teaching, and academic research, Dr. Vishwanathan is committed to advancing evidence-based pediatric urological care. His passion for education and patient-centered management makes him a valued speaker in the field.
Disclosures
Assimilate requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships for anyone with the ability to control the content of this educational activity have been reviewed and mitigated. Others involved in the planning of this activity have no relevant financial relationships.